Evaluation of Anti-PD-1 Therapy by Monitoring T Cell Responses in Melanoma, Lung and Other Cancer Types

Who May Qualify: - Are 18 years of age or older - Have histologic evidence of locally or regionally advanced or stage IV malignancy - Are considered appropriate for starting therapy with anti-PD-1/anti-PD-L1 monoclonal antibody by their treating physician (prior therapy with immune checkpoint inhibitor (ICI) is allowed) - Have an understanding of the protocol and its requirements, risks, and discomforts - Are willing to undergo peripheral blood collection at the time points mentioned in the protocol - Are able and willing to sign an willing to sign a consent form Who Should NOT Join This Trial: - Inability on the part of the patient to understand the willing to sign a consent form or be compliant with the protocol - Patients receiving any concurrent anti-cancer therapy or investigational agents (with the exception of an anti-PD-1/anti-PD-L1 agent as mentioned above) - Patients who are pregnant, nursing, or are of childbearing potential and are unwilling to employ adequate contraception Always talk to your doctor about whether this trial is right for you.